Putting the Pieces Together: How is the Mitochondrial Pathway of Apoptosis Regulated in Cancer and Chemotherapy?

Overview

Journal Cancer Metab

Publisher Biomed Central

Specialty Oncology

Date 2015 Jan 27

PMID 25621172

Citations 36

Authors

Rana Elkholi

Thibaud T Renault

Madhavika N Serasinghe

Jerry E Chipuk

Affiliations

Soon will be listed here.

Abstract

In order to solve a jigsaw puzzle, one must first have the complete picture to logically connect the pieces. However, in cancer biology, we are still gaining an understanding of all the signaling pathways that promote tumorigenesis and how these pathways can be pharmacologically manipulated by conventional and targeted therapies. Despite not having complete knowledge of the mechanisms that cause cancer, the signaling networks responsible for cancer are becoming clearer, and this information is serving as a solid foundation for the development of rationally designed therapies. One goal of chemotherapy is to induce cancer cell death through the mitochondrial pathway of apoptosis. Within this review, we present the pathways that govern the cellular decision to undergo apoptosis as three distinct, yet connected puzzle pieces: (1) How do oncogene and tumor suppressor pathways regulate apoptosis upstream of mitochondria? (2) How does the B-cell lymphoma 2 (BCL-2) family influence tumorigenesis and chemotherapeutic responses? (3) How is post-mitochondrial outer membrane permeabilization (MOMP) regulation of cell death relevant in cancer? When these pieces are united, it is possible to appreciate how cancer signaling directly impacts upon the fundamental cellular mechanisms of apoptosis and potentially reveals novel pharmacological targets within these pathways that may enhance chemotherapeutic success.

Citing Articles

Capsaicin (But Not Other Vanillins) Enhances Estrogen Binding to Its Receptor: Implications for Power Sports and Cancers.

Pietrowicz M, Root-Bernstein R Life (Basel). 2025; 15(2).

PMID: 40003617 PMC: 11856108. DOI: 10.3390/life15020208.

Autophagy is involved in the toxicity of the biocontrol agent GC16 against Tetranychus pueraricola (Acari: Tetranychidae) based on transcriptomic and proteomic analyses.

He Y, Du G, Wang G, Guan H, Zhu S, Chen B BMC Genomics. 2025; 26(1):119.

PMID: 39920625 PMC: 11806590. DOI: 10.1186/s12864-025-11312-7.

Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?.

Buonfiglio F, Bohm E, Pfeiffer N, Gericke A Antioxidants (Basel). 2023; 12(7).

PMID: 37508003 PMC: 10376185. DOI: 10.3390/antiox12071465.

Modulating p-AMPK/mTOR Pathway of Mitochondrial Dysfunction Caused by MTERF1 Abnormal Expression in Colorectal Cancer Cells.

Liu Q, Zhang L, Zou Y, Tao Y, Wang B, Li B Int J Mol Sci. 2022; 23(20).

PMID: 36293209 PMC: 9604058. DOI: 10.3390/ijms232012354.

Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.

Djuzenova C, Fischer T, Katzer A, Sisario D, Korsa T, Steussloff G BMC Cancer. 2021; 21(1):1201.

PMID: 34763650 PMC: 8582108. DOI: 10.1186/s12885-021-08930-1.

References

Gavathiotis E, Reyna D, Bellairs J, Leshchiner E, Walensky L . Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol. 2012; 8(7):639-45. PMC: 3617124. DOI: 10.1038/nchembio.995. View

Kitada S, Leone M, Sareth S, Zhai D, Reed J, Pellecchia M . Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003; 46(20):4259-64. DOI: 10.1021/jm030190z. View

Verhagen A, Ekert P, Pakusch M, Silke J, Connolly L, Reid G . Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000; 102(1):43-53. DOI: 10.1016/s0092-8674(00)00009-x. View

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-85. DOI: 10.1016/j.ccr.2007.07.001. View

Salvesen G, Abrams J . Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene. 2004; 23(16):2774-84. DOI: 10.1038/sj.onc.1207522. View

Kuwana T, Mackey M, Perkins G, Ellisman M, Latterich M, Schneiter R . Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002; 111(3):331-42. DOI: 10.1016/s0092-8674(02)01036-x. View

Dineen S, Roland C, Greer R, Carbon J, Toombs J, Gupta P . Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010; 70(7):2852-61. PMC: 2848888. DOI: 10.1158/0008-5472.CAN-09-3892. View

She Q, Solit D, Ye Q, OReilly K, Lobo J, Rosen N . The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005; 8(4):287-97. PMC: 3203692. DOI: 10.1016/j.ccr.2005.09.006. View

Delbridge A, Valente L, Strasser A . The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol. 2012; 4(11). PMC: 3536334. DOI: 10.1101/cshperspect.a008789. View

10.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

11.

Mohammad R, Goustin A, Aboukameel A, Chen B, Banerjee S, Wang G . Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007; 13(7):2226-35. DOI: 10.1158/1078-0432.CCR-06-1574. View

12.

Okada H, Suh W, Jin J, Woo M, Du C, Elia A . Generation and characterization of Smac/DIABLO-deficient mice. Mol Cell Biol. 2002; 22(10):3509-17. PMC: 133802. DOI: 10.1128/MCB.22.10.3509-3517.2002. View

13.

Joseph E, Pratilas C, Poulikakos P, Tadi M, Wang W, Taylor B . The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010; 107(33):14903-8. PMC: 2930420. DOI: 10.1073/pnas.1008990107. View

14.

Biswas S, Greene L . Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem. 2002; 277(51):49511-6. DOI: 10.1074/jbc.M208086200. View

15.

Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M . Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2007; 134(5):543-50. DOI: 10.1007/s00432-007-0317-7. View

16.

Gaizo Moore V, Brown J, Certo M, Love T, Novina C, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007; 117(1):112-21. PMC: 1716201. DOI: 10.1172/JCI28281. View

17.

Devarajan E, Sahin A, Chen J, Krishnamurthy R, Aggarwal N, Brun A . Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002; 21(57):8843-51. DOI: 10.1038/sj.onc.1206044. View

18.

Fang X, Yu S, Eder A, Mao M, Bast Jr R, Boyd D . Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999; 18(48):6635-40. DOI: 10.1038/sj.onc.1203076. View

19.

Kinoshita T, Yokota T, Arai K, Miyajima A . Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene. 1995; 10(11):2207-12. View

20.

Sengupta S, Harris C . p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 2005; 6(1):44-55. DOI: 10.1038/nrm1546. View